Blake Insomnia Therapeutics Announces Submitting Clinical Trial Application For Phase II Clinical Testing Post author:Sam Post published:August 24, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Watch Out: Cambridge Biotech Makes a Comeback January 16, 2018 3 Biotechs With the Biggest and Most Promising Pipelines February 15, 2017 IntelliPharmaCeutics Announces FDA Acceptance For Filing Of NDA For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain February 2, 2017
IntelliPharmaCeutics Announces FDA Acceptance For Filing Of NDA For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain February 2, 2017